WTI holds steady as traders weigh US-Iran tensions and supply risks
West Texas Intermediate (WTI) Oil trades little changed on Friday as traders weigh easing fears of an immediate US-Iran military escalation against persistent supply risks in the Strait of Hormuz. At the time of writing, WTI trades around $90.65 per barrel, up 0.10% on the day.
Oil prices pared some of their gains on Thursday after US President Donald Trump said Washington would not attack Iran before the November midterm elections while reiterating that Tehran would not be allowed to acquire a nuclear weapon.
US Vice President JD Vance also told Reuters earlier this week that Iran must make a “meaningful” reduction in its nuclear enrichment capacity to end the war. A senior Iranian official responded that Tehran would not give up its right to enrich uranium and said Washington’s proposals remain at odds with Iran’s demands.
Iran has also maintained that it will not reopen the Strait of Hormuz until its conditions are met. On Friday, Iran’s Islamic Revolutionary Guard Corps (IRGC) warned that vessels using what it considers unauthorised routes could be pursued beyond the Strait and across the wider region.
The latest warning followed reports from Iran’s Tasnim News that a large liquefied petroleum gas tanker had been hit and caught fire. The IRGC blamed the United States for the escalation in regional maritime tensions.
Elsewhere, the supply picture remains mixed. Regional crude exports are improving, led by Saudi Arabia after the restart of its East-West pipeline, which allows crude to reach the Red Sea without passing through the Strait of Hormuz. However, fighting between Saudi Arabia and the Houthis keeps risks to regional energy infrastructure elevated. Meanwhile, Hurricane Isaias has forced producers to shut down around 1.3 million barrels per day, or 62.9% of Gulf of Mexico Oil production.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
University of Michigan October Consumer Sentiment Index falls to a five-month low, with the Current Economic Conditions Indicator hitting a historic low
The University of Michigan’s Consumer Sentiment Index for October dropped to 46.3, below the market expectation of 47.6. The component reflecting current economic conditions decreased to 44.7, setting a new historical low, while the expectations component edged up to 47.3, marking its first rebound since July. Consumers’ one-year inflation expectations rose to 4.7%, and five-to-ten-year inflation expectations increased to 3.5%. According to the survey director, consumers from different political parties agree that the economic outlook has weakened compared to the beginning of the year.
Japan: Bond outflows reshape global yields - Commerzbank
BUZZ - JPMorgan gives “overweight” rating to LSD-based therapies, Definium stock rises
Latest Updates, October 9th - ** Definium Therapeutics (DFTX.O) shares rose 7.4% to $36.7 ** If the rally holds, the stock is set for its biggest single-day gain since June ** JPMorgan initiated coverage of the stock with an "Overweight" rating and a target price of $84 ** The bank stated that Definium’s lead candidate drug, DT120 ODT, has the potential to transform the treatment landscape for neuropsychiatric disorders ** Based on current data, the institution considers DT120 ODT (an LSD oral formulation for the treatment of major depressive disorder and generalized anxiety disorder) to be a "de-risked asset" ** The new target price implies a 145.7% upside from the latest closing price ** "While changes in the macro environment may present potential investment risks to the sector, we believe the positives for Definium outweigh the negatives," the bank stated ** A period of "frequent landmark events" is expected ahead, including plans to submit a new drug application to the FDA in the first half of 2027 ** The bank projects that total sales of DT120 orally disintegrating tablets (ODT) will approach $5 billion by 2035 ** Including intraday volatility, the stock has more than doubled in value year-to-date (For the convenience of non-English speakers, Reuters has automated this report’s translation into several other languages. Due to possible errors in automated translation or lack of full context, Reuters does not guarantee the accuracy of the automated translation and provides it solely as a convenience to readers. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)
BUZZ - UBS raises AbbVie’s target price, citing expansion of its core business beyond the immunology drug sector
On October 9, UBS raised its target price for AbbVie (ABBV.N) from $260 to $275, stating that investors' focus is shifting from blockbuster drugs Skyrizi and Rinvoq to the next wave of growth in its immunology business. UBS also noted that other projects in AbbVie’s R&D pipeline remain robust. It expects strong third-quarter performances from Skyrizi and Rinvoq, with respective sales reaching $5.7 billion and $2.7 billion. Special attention was given to upcoming combined treatment data of Skyrizi for Crohn's disease and ulcerative colitis, with mid-stage trial results to be released later this month. UBS believes that the drug lutikizumab, for inflammatory skin diseases, has a potential market size of $1-2 billion, and pointed out that Rinvoq sales are likely to surpass $500 million. The report also mentioned positive late-stage clinical data for cancer drugs Epkinly and etentamig, as well as the recent launch of the Parkinson’s disease medication tavapadon. UBS expects third-quarter earnings per share (EPS) to reach $3.76, within AbbVie’s forecast range of $3.73 to $3.77. Including intraday fluctuations, AbbVie’s stock has risen 21% so far this year. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several other languages. Due to potential inaccuracies or lack of required context in automated translations, Reuters does not guarantee the accuracy of these texts and is not liable for any damage or loss arising from their use. The translations are provided solely for readers' convenience.)
Crypto prices
More
